Equine antimicrobial therapy has advanced over time with the availability of increasing pharmacokinetic and pharmacodynamic studies in horses, allowing for greater evidence‐based clinical decision‐making. However, many challenges to optimal antimicrobial therapy remain and further research is needed to address these areas. There are a limited number of approved antimicrobials for use in horses, which creates a need for compounded preparations for clinicians. Extra‐label drug use is commonplace in equine practice, which warrants continual education of veterinarians about policies and updates. Performance and competitive horses have their own unique concerns when it comes to antimicrobial use and drug testing. In keeping with the use of a broader range of antimicrobials over time, antimicrobial resistance is emerging as an important issue facing veterinary medicine, including equine practice. Another challenge is that of drug interactions and adverse drug events for which there are little scientific data available for horses, especially for critically important diseases such as Rhodococcus equi infection. Finally, much progress has been made in the availability of equine‐specific antimicrobial susceptibility break points. These aid clinicians in interpreting culture and susceptibility results and antimicrobial selection. Even with these advances, continuing education and further research are needed in this area.

中文翻译：

---

马抗菌疗法：从业者当前和过去面临的问题

随着对马的药代动力学和药效学研究的不断增加，马的抗菌疗法随着时间的推移不断发展，从而可以做出更多的循证临床决策。然而，最佳抗菌治疗仍然存在许多挑战，需要进一步研究来解决这些领域。用于马的批准抗微生物剂数量有限，这为临床医生创造了对复合制剂的需求。在马实践中，标签外用药很常见，这需要对兽医进行有关政策和更新的持续教育。在抗菌素使用和药物测试方面，表现和有竞争力的马有自己独特的关注点。随着时间的推移，随着更广泛的抗菌药物的使用，抗微生物药物耐药性正在成为兽医，包括马业面临的一个重要问题。另一个挑战是药物相互作用和药物不良事件的问题，关于马的科学数据很少，尤其是对于非常重要的疾病，例如红球菌 等度感染。最后，在马特异性抗菌药物敏感性折点的可用性方面取得了很大进展。这些有助于临床医生解释培养和药敏结果以及抗生素选择。即使取得了这些进展，该领域仍需要继续教育和进一步研究。